Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,201-1,250 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__86_A8,5 | Lung | Primary cancer | 328 | Tumor/Malignant | 84.1% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__86_A8,6 | Lung | Primary cancer | 2,615 | Tumor/Malignant | 83.2% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__86_A8,7 | Lung | Primary cancer | 1,379 | Stromal | 47.2% | 0.86 | 0.40 |
| NSCLC_38242124__IMC__86_A8,8 | Lung | Primary cancer | 3,459 | Tumor/Malignant | 55.6% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__86_A8,9 | Lung | Primary cancer | 3,218 | Stromal | 31.0% | 0.72 | 0.64 |
| NSCLC_38242124__IMC__86_B1,1 | Lung | Primary cancer | 395 | Other | 45.1% | 0.37 | 0.91 |
| NSCLC_38242124__IMC__86_B1,10 | Lung | Primary cancer | 369 | Tumor/Malignant | 43.6% | 0.88 | 0.34 |
| NSCLC_38242124__IMC__86_B1,11 | Lung | Primary cancer | 2,966 | Tumor/Malignant | 38.5% | 0.77 | 0.55 |
| NSCLC_38242124__IMC__86_B1,12 | Lung | Primary cancer | 2,541 | Tumor/Malignant | 59.0% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__86_B1,13 | Lung | Primary cancer | 686 | Tumor/Malignant | 63.0% | 0.95 | 0.17 |
| NSCLC_38242124__IMC__86_B1,14 | Lung | Primary cancer | 1,671 | Immune | 27.5% | 0.93 | 0.21 |
| NSCLC_38242124__IMC__86_B1,2 | Lung | Primary cancer | 700 | Stromal | 28.4% | 0.35 | 0.96 |
| NSCLC_38242124__IMC__86_B1,3 | Lung | Primary cancer | 4,357 | Tumor/Malignant | 85.2% | 0.99 | 0.06 |
| NSCLC_38242124__IMC__86_B1,4 | Lung | Primary cancer | 2,910 | Tumor/Malignant | 34.0% | 0.94 | 0.24 |
| NSCLC_38242124__IMC__86_B1,5 | Lung | Primary cancer | 2,072 | Tumor/Malignant | 77.8% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__86_B1,6 | Lung | Primary cancer | 2,453 | Tumor/Malignant | 81.3% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__86_B1,7 | Lung | Primary cancer | 2,948 | Tumor/Malignant | 81.0% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__86_B1,8 | Lung | Primary cancer | 2,225 | Stromal | 32.4% | 0.93 | 0.23 |
| NSCLC_38242124__IMC__86_B1,9 | Lung | Primary cancer | 2,548 | Tumor/Malignant | 33.7% | 0.94 | 0.23 |
| NSCLC_38242124__IMC__86_B2,1 | Lung | Primary cancer | 2,150 | Tumor/Malignant | 32.1% | 0.88 | 0.34 |
| NSCLC_38242124__IMC__86_B2,11 | Lung | Primary cancer | 405 | Stromal | 40.5% | 0.38 | 0.96 |
| NSCLC_38242124__IMC__86_B2,12 | Lung | Primary cancer | 2,772 | Tumor/Malignant | 63.2% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__86_B2,13 | Lung | Primary cancer | 3,107 | Tumor/Malignant | 31.2% | 0.89 | 0.38 |
| NSCLC_38242124__IMC__86_B2,14 | Lung | Primary cancer | 786 | Tumor/Malignant | 30.0% | 0.91 | 0.32 |
| NSCLC_38242124__IMC__86_B2,2 | Lung | Primary cancer | 100 | Stromal | 58.0% | 0.69 | 0.65 |
| NSCLC_38242124__IMC__86_B2,3 | Lung | Primary cancer | 3,266 | Tumor/Malignant | 54.6% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__86_B2,4 | Lung | Primary cancer | 3,952 | Tumor/Malignant | 54.2% | 0.96 | 0.12 |
| NSCLC_38242124__IMC__86_B2,5 | Lung | Primary cancer | 1,063 | Tumor/Malignant | 53.5% | 0.95 | 0.12 |
| NSCLC_38242124__IMC__86_B2,6 | Lung | Primary cancer | 3,368 | Tumor/Malignant | 88.9% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__86_B3,1 | Lung | Primary cancer | 3,965 | Tumor/Malignant | 63.9% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__86_B3,10 | Lung | Primary cancer | 3,467 | Tumor/Malignant | 47.7% | 0.99 | 0.06 |
| NSCLC_38242124__IMC__86_B3,11 | Lung | Primary cancer | 1,306 | Stromal | 53.4% | 0.91 | 0.24 |
| NSCLC_38242124__IMC__86_B3,12 | Lung | Primary cancer | 4,546 | Tumor/Malignant | 44.5% | 1.00 | 0.05 |
| NSCLC_38242124__IMC__86_B3,13 | Lung | Primary cancer | 2,355 | Tumor/Malignant | 61.2% | 1.00 | 0.03 |
| NSCLC_38242124__IMC__86_B3,14 | Lung | Primary cancer | 959 | Tumor/Malignant | 79.5% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__86_B3,2 | Lung | Primary cancer | 2,582 | Tumor/Malignant | 33.7% | 0.84 | 0.43 |
| NSCLC_38242124__IMC__86_B3,3 | Lung | Primary cancer | 4,147 | Tumor/Malignant | 50.4% | 0.94 | 0.29 |
| NSCLC_38242124__IMC__86_B3,4 | Lung | Primary cancer | 4,451 | Immune | 41.6% | 0.89 | 0.29 |
| NSCLC_38242124__IMC__86_B3,6 | Lung | Primary cancer | 2,042 | Tumor/Malignant | 31.0% | 0.89 | 0.36 |
| NSCLC_38242124__IMC__86_B4,10 | Lung | Primary cancer | 1,347 | Tumor/Malignant | 86.9% | 0.98 | 0.05 |
| NSCLC_38242124__IMC__86_B4,12 | Lung | Primary cancer | 3,991 | Tumor/Malignant | 32.8% | 0.52 | 0.91 |
| NSCLC_38242124__IMC__86_B4,13 | Lung | Primary cancer | 2,843 | Tumor/Malignant | 88.1% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__86_B4,14 | Lung | Primary cancer | 2,510 | Tumor/Malignant | 65.9% | 0.97 | 0.09 |
| NSCLC_38242124__IMC__86_B4,2 | Lung | Primary cancer | 2,771 | Tumor/Malignant | 24.1% | 0.90 | 0.30 |
| NSCLC_38242124__IMC__86_B4,3 | Lung | Primary cancer | 1,020 | Stromal | 31.0% | 0.49 | 0.85 |
| NSCLC_38242124__IMC__86_B4,5 | Lung | Primary cancer | 291 | Tumor/Malignant | 67.7% | 0.34 | 0.96 |
| NSCLC_38242124__IMC__86_B4,6 | Lung | Primary cancer | 310 | Stromal | 63.9% | 0.42 | 0.78 |
| NSCLC_38242124__IMC__86_B4,7 | Lung | Primary cancer | 1,610 | Tumor/Malignant | 73.4% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__86_B4,8 | Lung | Primary cancer | 303 | Tumor/Malignant | 54.8% | 0.45 | 0.78 |
| NSCLC_38242124__IMC__86_B4,9 | Lung | Primary cancer | 685 | Stromal | 35.0% | 0.38 | 0.87 |